• Sellas Life Sciences posted a net loss of USD 8.41 million for the three months ended March 31, 2026, widening from USD 5.81 million a year earlier.
• Operating loss widened to USD 9.25 million from USD 6.06 million, as operating expenses climbed to USD 9.25 million from USD 6.06 million.
• Research and development expense rose to USD 5.13 million from USD 3.21 million, driven mainly by higher manufacturing costs tied to preparations for a potential BLA filing for GPS and higher clinical and regulatory consulting costs.
• General and administrative costs increased to USD 4.12 million from USD 2.86 million, due largely to higher legal fees linked to the 3DMed arbitration proceeding and higher consulting and public company costs.
• Cash and cash equivalents totaled USD 107.1 million at March 31, 2026, following USD 44.1 million of warrant-exercise proceeds during the quarter; REGAL Phase 3 GPS trial remained blinded with 78 pooled events as of May 11, 2026, with final analysis triggered at 80 events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001390478-26-000008), on May 12, 2026, and is solely responsible for the information contained therein.